ICOSLG and neoplasm: Targeting of ICOS within the context of tumor microenvironment using engineered cellular vaccines expressing ICOS ligand (ICOSL) has in particular been previously demonstrated to improve systemic efficacy of CTLA-4 blockade through potentiation of cytotoxic T cell function [85].